Pharmaceutical Industry Information Portal

HomeNews

News

FDA declines to approve AstraZeneca treatment for chronic nasal condition

AstraZeneca Plc said on Monday the U.S. drug regulator declined to approve its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps,...

Pfizer completes acquisition of Arena Pharmaceuticals for $6.7 billion

Pfizer Inc. announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of...

Abbvie to collaborate with Gedeon Richter in neuropsychiatric diseases

AbbVie and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for...

Japan’s Fujifilm to halt enrollment in drug Avigan® trial, targeting COVID-19 patients

A drug once hailed as Japan's biggest contribution in the global fight against COVID-19 suffered another setback, as Fujifilm Holdings Corp said it was...

New antimicrobial air filters rapidly kill SARS-CoV-2 in under 30 seconds, study shows

The antimicrobial filters are shown to kill pathogens, such as Candida albicans, Escherichia coli, and MRSA in under 15 min and to destroy SARS-CoV-2...

U.S FDA approves drug to treat early breast cancer

AstraZeneca and Merck reported today, Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative...
spot_img

Expert Articles

spot_img